LAB MONTHLY SUMMARY

Lab Name	**SRI SELLAM CLINICAL LAB**	**Lab No**	**13599**
Month	**July**	**Year**	**2020**
Constituent Group	**Chemistry I**		

Date of Result Entered : 31/07/2020

Date of Report Published : 14/08/2020

Sl.No	Analyte	Method / Principle Name	Analyzer Name	No of Participants	DV	Participants CV	Participants SD	Your Value	SDI	U
1	GLUCOSE	GOD-POD	Mindray	115	408.24	6.22	25.41	123 mg/dl	-11.23	4.74
2	UREA	UREASE UV / GLDH	Mindray	144	92.77	7.54	7.00	70.5 mg/dl	-3.18	1.17
3	CREATININE	JAFFE RATE-BLANKED &COMPENSATED/Alkaline Picrate	Biosystems	122	0.96	11.49	0.11	5.6 mg/dl	42.18	0.02
4	T.BILIRUBIN	DIAZONIUM SALT (Colorimetric) /JENDRASSIK	Mindray	102	4.04	11.20	0.45	5.77 mg/dl	3.84	0.09
5	T-PROTEIN	BIURET - colorimetric	Mindray	129	5.15	7.73	0.40	5.47 g/dl	0.80	0.07
6	ALBUMIN	BCG - colorimetric	Mindray	139	3.25	8.71	0.28	3.21 g/dl	-0.14	0.05
7	CALCIUM	ARSENAZO III	Biosystems	98	11.03	6.19	0.68	13.1 mg/dl	3.04	0.14
8	PHOSPHORUS	Molybdate UV/ Phosphomolybdate complex	Biosystems	59	3.41	13.61	0.46	4.8 mg/dl	3.02	0.12
9	URIC ACID	ENZYMATIC / URICASE Colorimetric	Mindray	129	7.38	8.13	0.60	6.85 mg/dl	-0.88	0.11
10	CHOLESTEROL	CHOD-PAP	Mindray	124	102.40	7.16	7.34	114 mg/dl	1.58	1.32
11	TRIGLYCERIDE	GPO-PAP / Enzymatic Colorimetric / End Point	Mindray	125	224.10	7.32	16.40	304 mg/dl	4.87	2.93
12	HDL CHO	DIRECT METHOD / Enzymatic colorimetric	Mindray	75	26.32	8.26	2.17	21 mg/dl	-2.45	0.50
13	SODIUM	ISE - Direct	Mindray	22	141.16	2.28	3.22	125.4 mmol/L	-4.89	1.37
14	POTASSIUM	ISE - Direct	Any Analyser	92	3.08	7.41	0.23	3.5 mmol/L	1.84	0.05
15	CHLORIDE	ISE - Direct	Any Analyser	61	109.19	4.08	4.46	102.9 mmol/L	-1.41	1.14
16	BICARBONATE	ENZYMATIC - PEPC (Phosphoenolpyruvate)	Biosystems	16	22.50	12.76	2.87	20 mmol/L	-0.87	1.44
17	AST	UV-Kinetic without PLP (P-5-P)	Mindray	127	208.87	12.58	26.27	48.9 U/L	-6.09	4.66
18	ALT	UV-Kinetic without PLP (P-5-P)	Mindray	116	128.98	18.76	24.20	245.6 U/L	4.82	4.49
19	ALP	PNP AMP KINETIC	Mindray	77	65.85	16.11	10.61	229 U/L	15.38	2.42
20	AMYLASE	CNPG3	Biosystems	124	43.77	15.58	6.82	84 U/L	5.9	1.22

SDI Range	Interpretation
Within -1.0 to +1.0	Excellent.
Between ±1.0 to ±2.0	Good.
Between ±2.0 to ±3.0	Accept with caution. Warning Signal.
Beyond ±3.0	Unacceptable performance. Action Signal.

Homogeneity and Stability of the sample is passed.

Contact details:
Email:clinqc@cmcvellore.ac.in
Contact Number: 0416-2283102

Pamela Christudoss

Dr. Pamela Christudoss
CMC EQAS Co-Ordinator
Christian Medical College, Vellore

********* End of Report ********

712010011371

Mrs. DHANALAKSHMI

PID NO: P712000015038

Age: 64 Year(s) Sex: Female

Reference:

Sample Collected At:
SRI SELLAM CLINICAL LAB
Near Panchamuga Vinayagar Koil,
638182

REPORT

VID: 712010011371

Registered On:
10/09/2020 01:40 PM

Collected On:
10/09/2020 1:40PM

Reported On:
10/09/2020 04:38 PM

HbA1C- Glycated Haemoglobin, blood by HPLC method

(EDTA Blood)

Investigation	Observed Value	Unit	Biological Reference Interval
HbA1C- Glycated Haemoglobin (HPLC)	11.5	%	Non-diabetic: <= 5.6 Pre-diabetic: 5.7-6.4 Diabetic: >= 6.5
Estimated Average Glucose (eAG)	283.35	mg/dL	

Interpretation & Remark:

1. HbA1c is used for monitoring diabetic control. It reflects the estimated average glucose (eAG).
2. HbA1c has been endorsed by clinical groups & ADA (American Diabetes Association) guidelines 2017, for diagnosis of diabetes using a cut-off point of 6.5%.
3. Trends in HbA1c are a better indicator of diabetic control than a solitary test.
4. Low glycated haemoglobin(below 4%) in a non-diabetic individual are often associated with systemic inflammatory diseases, chronic anaemia(especially severe iron deficiency & haemolytic), chronic renal failure and liver diseases. Clinical correlation suggested.
5. To estimate the eAG from the HbA1C value, the following equation is used: eAG(mg/dl) = 28.7*A1c-46.7
6. Interference of Haemoglobinopathies in HbA1c estimation.
   A. For HbF > 25%, an alternate platform (Fructosamine) is recommended for testing of HbA1c.
   B. Homozygous hemoglobinopathy is detected, fructosamine is recommended for monitoring diabetic status
   C. Heterozygous state detected (D10/ turbo is corrected for HbS and HbC trait).
7. In known diabetic patients, following values can be considered as a tool for monitoring the glycemic control. Excellent Control - 6 to 7 %, Fair to Good Control - 7 to 8 %, Unsatisfactory Control - 8 to 10 % and Poor Control - More than 10 % .

Note : Hemoglobin electrophoresis (HPLC method) is recommended for detecting hemoglobinopathy.

-- End of Report --

Dr. K.Anbu Lenin.,Md Pathology
MD (Pathology)